All Stories

  1. Understanding Hereditary Ataxias: A Historical Quest for Definition and Classification
  2. Somatosensory Evoked Potentials in Spinocerebellar Ataxia Type 3 and Type 10
  3. Ozzy Osbourne and Parkinson's disease: from darkness to awareness
  4. Revisiting Nomenclature in Movement Disorders: The Boundaries Between Pragmatism, Academicism, and Practical Applicability
  5. Targeting Cognitive Dysfunction in Spinocerebellar Ataxia Type 2 Through Digital Cognitive Training
  6. The cerebellum in dystonia: key player or background support?
  7. The cognitive cerebellum: a hub for motor, emotional, and executive control
  8. The cerebellum beyond motor control: cognitive dysfunction in spinocerebellar ataxias
  9. Gilles de La Tourette syndrome: the contribution of Guinon
  10. The cerebellar involvement in essential tremor: the connecting roads
  11. Cognitive Changes in Pre‐ataxic Spinocerebellar Ataxias: A Scoping Review
  12. Alix Joffroy (1844–1908)
  13. Spinocerebellar Ataxia Type 10 (SCA 10) in Brazil
  14. How great was the influence of his origins and descendants on Charcot's behaviors?
  15. Arquivos de Neuro-Psiquiatria: 82 years old, a new phase begins now
  16. Charcot's Russian pupils
  17. Fulgence Raymond: from rural life and veterinary medicine to Charcot's successor at La Salpêtrière Hospital
  18. A hiatus in the rivalry between Pierre Marie and Jules Dejerine: a collaborative study on sensory disorders by Andre Pierre Marie and Gustave Roussy
  19. The prominent role of Charcot and the French neurological tradition in Latin America
  20. François Rabelais and his dystonic giants
  21. The Huntington's Disease Gene Discovery
  22. Static posturography analysis for postural instability in patients with Parkinson’s disease
  23. Imbalance and gait impairment in Parkinson’s disease: discussing postural instability and ataxia
  24. Jean-Martin Charcot: the polymath
  25. Autosomal Recessive Cerebellar Ataxias: New Acronyms, Old Eponyms, and the Butterfly Life Cycle
  26. Chronic Pain And Levodopa Therapy in Parkinson’s Disease Patients
  27. The expulsion of Augusta Dejerine-Klumpke from the Salpêtrière Hospital: Pierre Marie's revenge
  28. The importance of the Brazilian Society of Neurological Investigation (SBIN)
  29. Thomas Willis' legacy on the 400th anniversary of his birth
  30. Inherited metabolic diseases mimicking hereditary spastic paraplegia (HSP): a chance for treatment
  31. Ramsay Hunt syndrome: New impressions in the era of molecular genetics
  32. “I’m gonna lose my strength, I’m gonna seize and die, And all that Jazz”! Neurological diseases in jazz legends
  33. Functionality and disease severity in spinocerebellar ataxias
  34. Evaluation of Brain SPECT with 99mTc‐TRODAT‐1 in the Differential Diagnosis of Parkinsonism
  35. Reply to: “Cognitive Impairments in Spinocerebellar Ataxia Type 10 and Their Relation to Cortical Thickness”
  36. Constantin von Economo´s 90th death anniversary
  37. Would Charcot’s “hystero-epilepsy” be a hypofunction of the NMDA receptors?
  38. Treatment of occipital neuralgia using onabotulinum toxin A
  39. Would Francisco Soca have been the first to relate toe phenomenon as pyramidal disorders?
  40. Spinocerebellar ataxia type 21 (TMEM240) with tremor and dystonia
  41. Patients with Cervical Dystonia Demonstrated Decreased Cognitive Abilities and Visual Planning Compared to Controls
  42. Freezing of gait (FOG) in Parkinson’s disease patients—the contribution of Garcin and Melaragno
  43. Reply
  44. It Is Time to Define Huntington's Disease Onset more Clearly
  45. Autosomal‐Recessive Cerebellar Ataxias and Movement Disorders With Elevated Alpha‐Fetoprotein
  46. Charcot: Buddhist Leanings?
  47. Nobel and Charcot in Paris: A Brazilian Connection?
  48. The Art of Charcot: An Outstanding Caricaturist
  49. Balance and physical functioning in Spinocerebellar ataxias 3 and 10
  50. Is Ataxia an Underestimated Symptom of Huntington's Disease?
  51. Follow-Up of Advanced Parkinson’s Disease Patients after Clinical or Surgical Emergencies: A Practical Approach
  52. The Role of the Cerebellum in Huntington’s Disease: a Systematic Review
  53. Upward Gaze Palsy: a Valuable Sign to Distinguish Spinocerebellar Ataxias
  54. Volumetric MRI Changes in Spinocerebellar Ataxia (SCA3 and SCA10) Patients
  55. Tribute to Professor Andrew J. Lees
  56. Comment on: “Investigation of intermediate CAG alleles of the HTT in the general population of Rio de Janeiro, Brazil, in comparison with a sample of Huntington disease‐affected families.”
  57. Neurology, psychiatry and the chess game: a narrative review
  58. Reply to Comment on: The Geographic Diversity of Spinocerebellar Ataxias (SCAs) in the Americas
  59. Assessment of ventilatory function in patients with spinocerebellar ataxia type 2
  60. Blepharospasm and periorbital edema after imatinib mesylate: improvement with botulinum toxin
  61. Charcot and His Passion for Dogs: A Historical Note
  62. Is fatigue an important finding in patients with spinocerebellar ataxia type 10 (SCA10)?
  63. The Duels of Pierre Marie and Jules Dejerine
  64. Reply to Comment on: The geographic diversity of spinocerebellar ataxias (SCAs) in the Americas: A systematic review
  65. Overcoming bashfulness: how cocaine aided Freud to summon the courage to meet Charcot
  66. Spinocerebellar ataxias in Southern Brazil: Genotypic and phenotypic evaluation of 213 families
  67. Nonmotor symptoms in spinocerebellar ataxias (SCAs)
  68. The Geographic Diversity of Spinocerebellar Ataxias (SCAs) in the Americas: A Systematic Review
  69. Charcot's paradox
  70. Sporadic adult-onset spinocerebellar ataxias
  71. Hyposkillia and spanophilia in the movement disorders rounds
  72. Reply to: Early distinction of Parkinson variant multiple system atrophy from Parkinson's disease
  73. The Legacy of Charles David Marsden: A Role Model in the Field of Movement Disorders
  74. The Melted Statue of Charcot: The Nazi Occupation of Paris During World War II
  75. The Effectiveness of Reality Orientation Therapy in the Treatment of Parkinson Disease Dementia
  76. Association between olfactory loss and cognitive deficits in Parkinson's disease
  77. Abnormal Findings in Polysomnographic Recordings of Patients with Spinocerebellar Ataxia Type 2 (SCA2)
  78. Édouard Brissaud: distinguished neurologist and Charcot’s pupil
  79. Yawning in neurology: a review
  80. “ Flâneur neurologique in paris” – A guide to pinpointing the houses of famous neurologists in the late XIX century
  81. Antisense Oligonucleotide Therapy for Spinocerebellar Ataxias: Good News for Terrible Diseases
  82. Sleep disorders in spinocerebellar ataxia type 10
  83. When multiple sclerosis and X-linked adrenoleukodystrophy are tangled
  84. Can the CERAD neuropsychological battery be used to assess cognitive impairment in Parkinson's disease?
  85. Broken dynasty: how Jean Batiste Charcot relinquished his father’s neurological empire to conquer the seven seas
  86. More than ataxia – Movement disorders in ataxia-telangiectasia
  87. Searching for neurological diseases in the Julio-Claudian dynasty of the Roman Empire
  88. Different Cerebellar Ataxia Phenotypes Associated with Mutations of the PNPLA6 Gene in Brazilian Patients with Recessive Ataxias
  89. Apathy and depression in Parkinson Disease Dementia
  90. Attention deficit hyperactivity disorder and drug addiction rehabilitation patients
  91. Neurophysiological and neuroimaging changes (crossed cerebrocerebellar atrophy) after prolonged non-convulsive status epilepticus
  92. Classification and Characteristics of Pain Associated with Parkinson’s Disease
  93. Tourette's syndrome in famous musicians
  94. Cerad battery can be used for the diagnosis of dementia in Parkinson's disease?
  95. Pain assessment in wearing off period of levodopa treatment for Parkinson’s disease
  96. Dysphagia in Dystonia
  97. Dysphagia in Parkinson’s Disease
  98. Pain Relief in Cervical Dystonia with Botulinum Toxin Treatment
  99. The genetics of the dystonias – a review based on the new classification of the dystonias
  100. The Effectiveness of Reality Orientation in the Treatment of Alzheimer’s Disease
  101. Abnormal Cerebrovascular Reactivity in Patients with Parkinson’s Disease
  102. Genetic evaluation for TOR1-A (DYT1) in Brazilian patients with dystonia
  103. Evolution of the concept of dystonia
  104. Cervical dystonia: about familial and sporadic cases in 88 patients
  105. Cervical dystonia: clinical and therapeutic features in 85 patients
  106. Movement disorders secondary to long-term treatment with cyclosporine A
  107. Frequency of obsessive and compulsive symptoms in patients with blepharospasm and hemifacial spasm
  108. Frequency of obsessive and compulsive symptoms in patients with blepharospasm and hemifacial spasm
  109. Uso do propranolol de ação prolongada em 40 pacientes com tremor essencial e virgens de tratamento: um ensaio clínico não controlado
  110. Myotonia congenita and myoadenylate deaminase deficiency: case report
  111. Hemimasticatory spasm treated with botulinum toxin: case report
  112. Machado-Joseph disease versus hereditary spastic paraplegia: case report
  113. Hereditary spastic paraplegia associated with thin corpus callosum
  114. Reversible posterior leucoencephalopathy syndrome associated with bone marrow transplantation
  115. Acidente vascular cerebral em pacientes jovens: análise de 164 casos
  116. Alpha-Synucleinopathies
  117. Neurosurgical Treatments of Neurodegenerative Disorders
  118. Stroke